Literature DB >> 12610169

Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both?

Charles A Schiffer.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12610169     DOI： 10.1200/JCO.2003.11.116

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

Review 1.  Pediatric-like therapy for adults with ALL.

Authors:  Hervé Dombret; Thomas Cluzeau; Françoise Huguet; Nicolas Boissel
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

Review 2.  Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults.

Authors:  Ryan Mattison; Wendy Stock
Journal:  Curr Hematol Malig Rep       Date:  2008-07       Impact factor: 3.952

Review 3.  Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.

Authors:  Eric S Schafer; Stephen P Hunger
Journal:  Nat Rev Clin Oncol       Date:  2011-05-31       Impact factor: 66.675

4.  Implementation of a pharmacist-initiated pharmaceutical handover for oncology and haematology patients being transferred to critical care units.

Authors:  John Coutsouvelis; Carmela E Corallo; Michael J Dooley; Josephine Foo; Ann Whitfield
Journal:  Support Care Cancer       Date:  2009-08-07       Impact factor: 3.603

Review 5.  Acute myelogenous leukemia in adolescents and young adults.

Authors:  Ursula Creutzig; Matthew A Kutny; Ronald Barr; Richard F Schlenk; Raul C Ribeiro
Journal:  Pediatr Blood Cancer       Date:  2018-04-18       Impact factor: 3.167

6.  Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.

Authors:  Anjali S Advani; Eric Larsen; Kristina Laumann; Selina M Luger; Michaela Liedtke; Meenakshi Devidas; Zhiguo Chen; Jun Yin; Matthew C Foster; David Claxton; Kristin Coffan; Martin S Tallman; Frederick R Appelbaum; Harry Erba; Richard M Stone; Stephen P Hunger; Jennifer L McNeer; Mignon L Loh; Elizabeth Raetz; Naomi Winick; William Carroll; Richard A Larson; Wendy Stock
Journal:  Blood Adv       Date:  2021-01-26

Review 7.  L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.

Authors:  Rob Pieters; Stephen P Hunger; Joachim Boos; Carmelo Rizzari; Lewis Silverman; Andre Baruchel; Nicola Goekbuget; Martin Schrappe; Ching-Hon Pui
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

8.  Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.

Authors:  Anita J Kumar; Phyllis A Gimotty; Joel M Gelfand; Georgina Buck; Jacob M Rowe; Anthony H Goldstone; Adele Fielding; David I Marks; Mark Litzow; Elisabeth Paietta; Hillard M Lazarus; Martin S Tallman; Selina M Luger; Alison W Loren
Journal:  Am J Hematol       Date:  2016-08-22       Impact factor: 10.047

9.  Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models.

Authors:  Antoine J Harb; Wei Tan; Gregory E Wilding; LaurieAnn Ford; Sheila N J Sait; AnneMarie W Block; Maurice Barcos; Paul K Wallace; Eunice S Wang; Meir Wetzler
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

10.  What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.

Authors:  Wendy Stock; Mei La; Ben Sanford; Clara D Bloomfield; James W Vardiman; Paul Gaynon; Richard A Larson; James Nachman
Journal:  Blood       Date:  2008-05-23       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.